<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687086</url>
  </required_header>
  <id_info>
    <org_study_id>18-001009</org_study_id>
    <secondary_id>R01AG057929</secondary_id>
    <nct_id>NCT03687086</nct_id>
  </id_info>
  <brief_title>Sleep Without Insomnia or The Use of Chronic Hypnotics</brief_title>
  <acronym>SWITCH</acronym>
  <official_title>A Novel Mechanism for Helping Older Adults Discontinue Use of Sleeping Pills</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleeping medications, called hypnotics, are often prescribed for insomnia and are associated
      with adverse health outcomes in older adults. Response rates to hypnotic discontinuation
      programs are often inadequate, and many patients eventually resume use of hypnotics,
      suggesting that other mechanisms need to be targeted to achieve and sustain high rates of
      non-use. Current programs focus on the tapering of hypnotics and/or the treatment of insomnia
      symptoms. These programs employ strategies such as supervised gradual taper, cognitive
      behavioral therapy targeting hypnotic withdrawal, and/or cognitive behavioral therapy for
      insomnia. Evidence suggests that another mechanism involving &quot;placebo&quot; effects may be a
      viable target for achieving and sustaining higher discontinuation rates. Cognitive
      expectancies play a key role in producing placebo effects, which are characterized as real
      improvements in sleep arising from psychosocial aspects of treatment rather than drug effects
      alone. In this study, investigators are comparing two programs for discontinuing hypnotic
      medications-a program that addresses placebo effects associated with hypnotic use and a
      program that does not address these effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will complete a 5-year randomized trial, recruiting participants from two
      healthcare systems using a three-step screening process that minimizes time and travel burden
      to participants. Step 1 (identification of participants): Investigators will identify
      participants aged &gt;= 55 years who have current prescriptions for lorazepam, temazepam,
      alprazolam, and/or zolpidem for &gt;= 3 months. Investigators will use three sources to identify
      these patients: medication lists from electronic health records/administrative data, consults
      to insomnia clinic, and referrals from providers. The research team will mail a recruitment
      letter (with opt-out card) to patients identified from these sources. Step 2 (phone screening
      for current or prior insomnia and current hypnotic use); Patients who endorse a history of
      insomnia symptoms and current hypnotic use will be invited for an in-person screening. Step 3
      (in-person screening for remaining eligibility criteria (and baseline assessments): After
      written consent, the in-person screening visit consists of a comprehensive sleep, mental
      health, and brief physical health assessment. Individuals who meet study criteria and agree
      to continue will be randomized to receive either the Program A (N=94) or Program B (N=94).
      The interventions are approximately 2 months. Following intention-to-treat principles, all
      randomized participants will complete an assessment immediately after the intervention ends
      and 6 months after completing treatment. Participants will be compensated monetarily for
      assessment visits. Investigators will measure hypnotic expectancies, hypnotic
      discontinuation, and insomnia severity post-treatment and at 6-months follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 11, 2018</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of hypnotic discontinuation</measure>
    <time_frame>6 months after treatment ends</time_frame>
    <description>Rates of discontinuation of target medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>An average of 9 weeks from randomization and 6 months after treatment ends</time_frame>
    <description>Insomnia severity based on self-report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysfunctional Beliefs and Attitudes About Sleep - Medication Scale ratings</measure>
    <time_frame>An average of 9 weeks from randomization and 6 months after treatment ends</time_frame>
    <description>Expectancies for hypnotics based on self-report (range 0 to 10; average score of medication items)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of hypnotic discontinuation</measure>
    <time_frame>An average of 9 weeks from randomization</time_frame>
    <description>Rates of hypnotic discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypnotic dose</measure>
    <time_frame>An average of 9 weeks from randomization</time_frame>
    <description>Dose of hypnotic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypnotic dose</measure>
    <time_frame>6 months after treatment ends</time_frame>
    <description>Dose of hypnotic</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Digit Symbol Substitution</measure>
    <time_frame>An average of 9 weeks from randomization and 6 months after treatment ends</time_frame>
    <description>Objective measure of processing speed</description>
  </other_outcome>
  <other_outcome>
    <measure>Mini-Mental State Examination</measure>
    <time_frame>An average of 9 weeks from randomization and 6 months after treatment ends</time_frame>
    <description>Measure of cognition</description>
  </other_outcome>
  <other_outcome>
    <measure>Trails A&amp;B</measure>
    <time_frame>An average of 9 weeks from randomization and 6 months after treatment ends</time_frame>
    <description>Objective measure of cognition</description>
  </other_outcome>
  <other_outcome>
    <measure>One-leg Balance test</measure>
    <time_frame>An average of 9 weeks from randomization and 6 months after treatment ends</time_frame>
    <description>Objective measure of balance</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>Program A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cognitive behavioral therapy type A plus medications in packaging type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Program B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cognitive behavioral therapy type B plus medications in packaging type B</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Program A</intervention_name>
    <description>Cognitive behavioral therapy type A plus medications prepared in packaging type A.</description>
    <arm_group_label>Program A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Program B</intervention_name>
    <description>Cognitive behavioral therapy type B plus medications in packaging type B.</description>
    <arm_group_label>Program B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 55 years

          -  Use of lorazepam, alprazolam, temazepam,and/or zolpidem for current or prior insomnia
             symptoms 2 or more nights per week for at least 3 months

          -  Current or prior insomnia symptoms

          -  Available to attend weekly in-person sessions over 9 weeks

        Exclusion Criteria:

        High risk for complications in outpatient hypnotic discontinuation program:

          -  Seizure disorder

          -  Supratherapeutic or high baseline hypnotic dose (&gt; diazepam-equivalent of 8 mg/night).

          -  High baseline risk of complicated withdrawal;benzodiazepine intoxication or current or
             past symptoms of complicated benzodiazepine/alcohol withdrawal (e.g.,seizure, delirium
             at baseline (prior to taper))

          -  Polydrug use (e.g., chronic high dose opioids)

          -  Unable to keep study medications in secure location

          -  Evidence of prescription fraud (e.g., multiple prescriptions for same drug filled at
             multiple pharmacies during overlapping time periods, diversion)

        Discontinuation of hypnotic not appropriate:

        â€¢Study-targeted hypnotic used to treat another clinical condition (e.g., panic disorder)

        Poor candidate for cognitive behavioral therapy for insomnia:

          -  Presence of bipolar disorder

          -  Cognitive impairment (e.g., Mini-Mental State Examination &lt; 24)

          -  Sleep/wake difficulty is better explained by another sleep disorder such as restless
             legs syndrome, narcolepsy, insufficient sleep syndrome, or circadian rhythm sleep-wake
             disorders

          -  Untreated sleep-disordered breathing (respiratory event index &gt;= 15)

          -  Medically/psychiatrically unstable (e.g., planned major surgery during the study
             period;psychosis, suicidal, active alcohol/substance abuse based on history and
             medical records)

          -  Unstable housing situation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constance Fung, MD, MSHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA, VA Greater Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Greater Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Constance Fung, MD, MSHS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Compliance at one of the sites is not permitting data sharing.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

